Results 201 to 210 of about 26,025 (223)

Venetoclax

Reactions Weekly, 2022
  +8 more sources

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

Cancers, 2022
David C De Leeuw, Jeroen Jwm Janssen
exaly  

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

Hematological Oncology, 2022
Deanna Brackman, Rajeev Menon, Ahmed Hamed Salem   +2 more
exaly  

Venetoclax

Reactions Weekly, 2019
  +7 more sources

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia

International Journal of Molecular Sciences, 2022
Adir Shaulov, Arnon Haran, Vladimir Vainstein   +2 more
exaly  

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Cancer, 2021
Kunhwa Kim, Abhishek Maiti Mbbs, Sanam Loghavi   +2 more
exaly  

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study

Cancers, 2023
Eyal Lebel, Efstathios Kastritis, Giovanni Palladini   +2 more
exaly  

Targeting NF-κB–dependent alkaliptosis for the treatment of venetoclax-resistant acute myeloid leukemia cells

Biochemical and Biophysical Research Communications, 2021
Rui Kang, Minghua Yang, Daolin Tang
exaly  

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

Oncologist, 2022
Pankit Vachhani, Grace Ku
exaly  

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

Annals of Oncology, 2017
Nicole Lamanna, Jeffrey J Pu
exaly